Literature DB >> 10698811

Development of major depression after treatment for smoking cessation.

J Y Tsoh1, G L Humfleet, R F Muñoz, V I Reus, D T Hartz, S M Hall.   

Abstract

OBJECTIVE: Case studies suggest cigarette abstinence may precipitate a major depressive episode. This study examined the incidence and predictors of major depression in the 12 months after treatment for smoking cessation.
METHOD: Participants (N=304, 172 women) were recruited from two trials of smoking cessation. Both trials provided psychological group intervention, but one group received treatment with nicotine gum and the other was given nortriptyline or placebo. The incidence of major depressive episodes was identified by the Inventory to Diagnose Depression, which was administered at follow-up assessments.
RESULTS: The 12-month incidence of major depression after treatment for smoking cessation was 14.1% (N=43). Multiple logistic regression analyses indicated that history of depression, baseline Beck Depression Inventory score, college education, and age at smoking initiation were significant predictors of major depression after treatment. Abstinence at the end of treatment did not significantly predict major depression.
CONCLUSIONS: Patients who achieved abstinence from smoking showed a risk of developing depressive episodes similar to those who failed to achieve abstinence. As expected, patients who had a history of depression were more likely to experience depressive episodes after treatment for smoking cessation. The 12-month incidence of major depression in this study group was higher than that observed in the general population, but reasons for the elevation were not clear.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698811     DOI: 10.1176/appi.ajp.157.3.368

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  55 in total

Review 1.  Genetics of smoking and depression.

Authors:  Ming T Tsuang; Tracee Francis; Kyle Minor; Alison Thomas; William S Stone
Journal:  Hum Genet       Date:  2012-04-17       Impact factor: 4.132

2.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

3.  Therapeutic drug monitoring of nortriptyline in smoking cessation: a multistudy analysis.

Authors:  M E Mooney; V I Reus; J Gorecki; S M Hall; G L Humfleet; R F Muñoz; K Delucchi
Journal:  Clin Pharmacol Ther       Date:  2007-08-08       Impact factor: 6.875

Review 4.  Smoking and suicide: a brief overview.

Authors:  John R Hughes
Journal:  Drug Alcohol Depend       Date:  2008-08-03       Impact factor: 4.492

5.  The impact of quitting smoking on depressive symptoms: findings from the International Tobacco Control Four-Country Survey.

Authors:  Jae Cooper; Ron Borland; Hua-Hie Yong; Omid Fotuhi
Journal:  Addiction       Date:  2016-04-15       Impact factor: 6.526

Review 6.  The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations.

Authors:  Jaimee L Heffner; Jeffrey R Strawn; Melissa P DelBello; Stephen M Strakowski; Robert M Anthenelli
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

7.  Financial incentives for smoking cessation among depression-prone pregnant and newly postpartum women: effects on smoking abstinence and depression ratings.

Authors:  Alexa A Lopez; Joan M Skelly; Stephen T Higgins
Journal:  Nicotine Tob Res       Date:  2015-04       Impact factor: 4.244

8.  Efficacy of bupropion for relapse prevention in smokers with and without a past history of major depression.

Authors:  Lisa Sanderson Cox; Christi A Patten; Raymond S Niaura; Paul A Decker; Nancy Rigotti; David P L Sachs; A Sonia Buist; Richard D Hurt
Journal:  J Gen Intern Med       Date:  2004-08       Impact factor: 5.128

9.  [Swallowing disorders after partial laryngectomy. Prevalence and predictors].

Authors:  A Meyer; A Dietz; D Wollbrück; J Oeken; H Danker; E F Meister; A Sandner; W Völkel; E Brähler; S Singer
Journal:  HNO       Date:  2012-10       Impact factor: 1.284

Review 10.  Duality of Antidepressants and Neuroprotectants.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2015-11-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.